Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

This trial is testing a new combination approach for adults aged 40 and older who are newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) — an aggressive blood cancer — and whose cancer does not carry the Philadelphia chromosome (a specific genetic change). The treatment sequence uses blinatumomab and venetoclax together, followed by inotuzumab ozogamicin, aiming to achieve deep remission without needing intensive chemotherapy. **You may be eligible if...** - You are 40 or older with newly diagnosed Philadelphia chromosome-negative B-cell ALL - Your performance status is acceptable (ECOG 0-2) with a life expectancy of at least 3 months - Your heart, liver, and kidney functions are adequate **You may NOT be eligible if...** - Your leukemia has spread to the brain or spinal cord - You have had another cancer in the past 5 years (except localized thyroid or skin cancers) - You have heart failure with an ejection fraction below 45% - You have HIV or other serious active health conditions Talk to your doctor to see if this trial is right for you.